/C O R R E C T I O N -- Nu Skin Enterprises, Inc./

              /C O R R E C T I O N -- Nu Skin Enterprises, Inc./

PR Newswire

PROVO, Utah, Aug. 1, 2013

In the news release, Nu Skin Enterprises Reports Record Second-Quarter
Results, issued 01-Aug-2013 by Nu Skin Enterprises, Inc. over PR Newswire, the
earnings release included an inadvertent typographical error. While the annual
guidance of $2.91 to $2.95 billion in revenue and the annual earnings per
share of $5.05 to $5.15, as well as the revenue guidance for the third quarter
of $790 to $810 million were correctly stated, the last sentence in the third
paragraph of the Outlook section contained an error. The earnings per share
guidance for the third quarter should have been "$1.35 to $1.40." The
complete, corrected release follows:

  Nu Skin Enterprises Reports Record Second-Quarter Results

    Company raises annual sales forecast $90 million

PROVO, Utah, Aug. 1, 2013 /PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE:
NUS) today announced record second-quarter results with revenue of $682.9
million, a 15 percent increase over the prior-year period. Revenue for the
quarter was negatively impacted 3 percent by foreign currency fluctuations.
Quarterly earnings per share increased 30 percent to $1.22 from $0.94 in the
prior year.

"We are extremely pleased with second-quarter results that reflect the strong
momentum of the business," said Truman Hunt, president and chief executive
officer. "We are particularly pleased with these results given the record
regional ageLOC product launches in the prior-year period. Additionally, we
generated continued growth of both our consumer and sales leader base,
reflected in 32 percent growth in actives and 23 percent growth in sales
leaders. Overall, we saw healthy trends throughout the global business,
particularly in the Greater China, North Asia and Americas regions."

"Sales force enthusiasm for the introduction of our ageLOC TR90 weight
management system bodes well for a strong second half of the year. We plan to
begin the limited-time offer of ageLOC TR90 in September and believe this new
product provides an ideal vehicle for us to increase our presence in the
growing weight management category."

Regional Results

Greater China. In Greater China, second-quarter revenue increased 35 percent
to $269.1 million, compared to $199.7 million in the prior year, which
included approximately $100 million in product launch revenue. The region's
results were negatively impacted 3 percent by foreign currency fluctuations.
The sales leader count in the region improved 51 percent, while the number of
actives increased 121 percent compared to the prior year.

North Asia. Second-quarter revenue in North Asia was $196.8 million, compared
to $177.7 million for the same period of 2012. The region's results were
negatively impacted 12 percent by foreign currency fluctuations. Japan
local-currency revenue improved 5 percent and South Korea generated
local-currency revenue growth of 54 percent. The number of sales leaders in
the region was up 21 percent while the number of actives improved 15 percent.

South Asia/Pacific. Revenue in South Asia/Pacific was $85.9 million, a 13
percent decline compared to the prior year. Revenue in the prior year included
approximately $40 million in product launch sales. Results were not notably
impacted by foreign currency fluctuations. The region's second-quarter sales
leaders decreased 20 percent while actives increased 16 percent compared to
the same period in 2012.

Americas. Revenue in the Americas improved 17 percent to $84.3 million,
compared to $71.8 million in the prior-year period. The region's results were
negatively impacted 5 percent by foreign currency fluctuations. The number of
sales leaders in the region improved 16 percent while the number of actives
increased 3 percent compared to the prior year.

EMEA. Revenue in the EMEA region was $46.8 million, a 2 percent improvement
over the prior-year period. The region's results were positively impacted 1
percent by foreign currency fluctuations. Sales leaders decreased 3 percent,
while actives increased 4 percent compared to the prior year. 

Operational Performance

The company's operating margin was 16.8 percent for the quarter, compared to
16.5 percent, while gross margin was 83.7 percent, compared to 83.9 percent in
the prior year. Selling expenses, as a percent of revenue, were 45.2 percent
in the second quarter. General and administrative expenses, as a percent of
revenue, improved to 21.7 percent from 22.3 percent in the prior-year period.
Other income (expense) reflected an expense of $1.1 million compared to a $3.4
million expense in the prior year.

The company's income tax rate for the quarter was 34.4 percent compared to
36.1 percent in the prior-year period. The company's cash and short-term
investment position at the end of the quarter was $411.4 million. Dividend
payments were $17.6 million.

Outlook

"As we look to the back half of the year, we are ramping up for what we expect
to be our largest-ever product launch," said Hunt. "Given the growth momentum
of the business, we are again increasing the sales forecast for the remainder
of the year. We expect the upcoming launch of ageLOC TR90 and the strength of
the business in several key markets will lead to another record year as annual
revenue will approach the $3 billion mark," Hunt concluded.

"Given the significant growth in our actives, we are raising our annual sales
guidance by $90 million to $2.91 to $2.95 billion," said Ritch Wood, chief
financial officer. We now expect earnings per share to be $5.05 to $5.15 and
continue to project a negative 5 percent foreign currency impact to annual
revenue."

"In the third quarter, we will introduce ageLOC TR90 for a limited time in the
Greater China region and much of South Asia in advance of our global
convention," continued Wood. "With these ageLOC TR90 sales, we anticipate
third-quarter revenue to be between $790 and $810 million, with a negative
currency impact to revenue of 6 to 7 percent. We anticipate earnings per share
to be $1.35 to $1.40 for the quarter," concluded Wood.

The company's management will host a webcast with the investment community on
Aug. 1, 2013, at 11 a.m. EDT. Those wishing to access the webcast, as well as
the financial information presented during the call, can visit the Investor
Relations page on Nu Skin Enterprises' website, http://ir.nuskin.com. An
archive of the webcast will be available at this same URL through Aug. 16,
2013.

About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its
comprehensive anti-aging product portfolio, independent business opportunity
and corporate social responsibility initiatives. The company's scientific
leadership in both skin care and nutrition has established Nu Skin as a
premier anti-aging company. The company's anti-aging products feature the new
ageLOC^® suite of products including the ageLOC^® R^2 nutritional supplement,
ageLOC^® Galvanic Spa System and ageLOC^® Galvanic Body Spa™, as well as the
ageLOC^® Transformation daily skin care system. A global direct selling
company, Nu Skin operates in 53 markets worldwide and is traded on the New
York Stock Exchange under the symbol "NUS." More information is available at
http://www.nuskin.com.

Please Note: This press release, particularly the "Outlook" section, contains
forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended that represent the company's current expectations and
beliefs. All statements other than statements of historical fact are
"forward-looking statements" for purposes of federal and state securities laws
and include, but are not limited to, statements of management's expectations
regarding the company's performance, initiatives, strategies, new product
introductions and growth in the company's markets, including mainland China;
statements of projections regarding revenue, earnings per share, foreign
currency impact and other financial items; statements of belief; and
statements of assumptions underlying any of the foregoing. In some cases, you
can identify these statements by forward-looking words such as "believe,"
"expect," "project," "anticipate," "estimate," "intend," "plan," "targets,"
"likely," "will," "would," "could," "may," "might," the negative of these
words and other similar words.

The forward-looking statements and related assumptions involve risks and
uncertainties that could cause actual results and outcomes to differ
materially from any forward-looking statements or views expressed herein.
These risks and uncertainties include, but are not limited to, the following:

  oany failure of current or planned initiatives or products to generate
    interest among distributors and customers and generate sponsoring and
    selling activities on a sustained basis;
  orisks related to accurately predicting, delivering or maintaining
    sufficient quantities of products to support our planned initiatives or
    launch strategies, including possible ingredient supply limitations;
  ochallenging economic conditions globally;
  orisk of foreign currency fluctuations and the currency translation impact
    on the company's business associated with these fluctuations;
  orisks associated with general inquiries and complaints to consumer
    protection agencies in Japan regarding the activities of some
    distributors;
  orisks associated with our ability to manage rapid growth, particularly in
    our greater China region;
  oregulatory risks associated with the company's products, which could
    require the company to modify its claims or inhibit the company's ability
    to import or continue selling a product in a market if it is determined to
    be a medical device or if it is unable to register the product in a timely
    manner under applicable regulatory requirements;
  ocontinued regulatory scrutiny and investigations in Mainland China, which
    have from time to time in the past, and could in the future, negatively
    impact the company's business, including the interruption of sales
    activities in stores, loss of licenses, and the imposition of fines;
  oadverse publicity related to the company's business, products, industry or
    any legal actions or complaints by distributors or others;
  oany prospective or retrospective increases in duties on the company's
    products imported into the company's markets outside of the United States
    and any adverse results of tax audits or unfavorable changes to tax laws
    in the company's various markets; and
  ocontinued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements
contained herein are further qualified by a detailed discussion of associated
risks set forth in the documents filed by the company with the Securities and
Exchange Commission. The forward-looking statements set forth the company's
beliefs as of the date that such information was first provided and the
company assumes no duty to update the forward-looking statements contained in
this release to reflect any change except as required by law.





NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
For the Second Quarters Ended June 30, 2013 and 2012
(in thousands, except per share amounts)
                                  2013                   2012
Revenue:
 Greater China             $               $       
                                  269,146                199,728
 North Asia                196,757                177,695
  South Asia/Pacific        85,916                 98,344
  Americas                  84,289                 71,766
  EMEA                      46,819                 45,702
Total revenue                     682,927                593,235
Cost of sales                     111,273                95,584
Gross profit                      571,654                497,651
Operating expenses:
 Selling expenses          308,769                267,363
 General and               148,302                132,376
administrative expenses
Total operating expenses          457,071                399,739
Operating income                  114,583                97,912
Other income (expense), net       (1,187)                (3,369)
Income before provision for       113,396                94,543
income taxes
Provision for income taxes        38,961                 34,136
Net income                        $              $        
                                  74,435                 60,407
Net income per share:
 Basic                     $            $          
                                  1.27                   0.98
 Diluted                   $            $          
                                  1.22                   0.94
Weighted average common shares
outstanding:
 Basic                     58,620                 61,706
 Diluted                   61,121                 64,230

NU SKIN ENTERPRISES, INC.
Consolidated Statements of Income (Unaudited)
For the Six Month Periods Ended June 30, 2013 and 2012
(in thousands, except per share amounts)
                                  2013                   2012
Revenue:
 Greater China             $               $       
                                  444,852                292,339
 North Asia                384,950                359,895
  South Asia/Pacific        153,158                175,665
  Americas                  160,830                138,106
  EMEA                      89,231                 89,232
Total revenue                     1,233,021              1,055,237
Cost of sales                     201,318                171,340
Gross profit                      1,031,703              883,897
Operating expenses:
 Selling expenses          550,652                469,898
 General and               283,809                244,424
administrative expenses
Total operating expenses          834,461                714,322
Operating income                  197,242                169,575
Other income (expense), net       (1,075)                266
Income before provision for       196,167                169,841
income taxes
Provision for income taxes        67,450                 61,605
Net income                        $               $       
                                  128,717                108,236
Net income per share:
 Basic                     $            $          
                                  2.20                   1.75
 Diluted                   $            $          
                                  2.11                   1.67
Weighted average common shares
outstanding:
 Basic                     58,487                 62,016
 Diluted                   60,882                 64,773

NU SKIN ENTERPRISES, INC.
Consolidated Balance Sheets (Unaudited)
(in thousands)
                                          June 30, 2013      December 31, 2012
ASSETS
Current assets:
 Cash and cash equivalents         $           $       
                                          402,678           320,025
 Current investments               8,754              13,378
 Accounts receivable               59,043             36,850
 Inventories, net                  178,183            135,874
  Prepaid expenses and other        117,138            93,276
                                          765,796            599,403
Property and equipment, net               304,619            229,787
Goodwill                                  112,446            112,446
Other intangible assets, net              87,644             92,518
Other assets                              122,202            118,753
  Total assets              $            $      
                                          1,392,707          1,152,907
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 Accounts payable                  $          $        
                                          48,954            47,882
 Accrued expenses                  355,215            233,202
 Current portion of long-term debt 69,461             39,019
                                          473,630            320,103
Long-term debt                            128,664            154,963
Other liabilities                         98,326             87,229
 Total liabilities         700,620            562,295
Stockholders' equity:
 Class A common stock              91                 91
  Additional paid-in capital        332,588            317,293
 Treasury stock, at cost            (718,800)          (714,853)
  Accumulated other comprehensive   (55,272)           (51,822)
loss
  Retained earnings                 1,133,480          1,039,903
                                          692,087            590,612
  Total liabilities and     $            $      
stockholders' equity                      1,392,707          1,152,907

NU SKIN ENTERPRISES, INC.

Actives/Sales Leaders Statistics
                    As of June 30, 2013      As of June 30,  % Increase
                                             2012            (Decrease)
                    Actives     Sales    Actives    Sales    Actives  Sales
                                Leaders             Leaders           Leaders
Greater China       376,000     30,455   170,000    20,182   121.2%   50.9%
North Asia          389,000     17,372   337,000    14,370   15.4%    20.9%
South Asia/Pacific  114,000     7,120    99,000     8,856    15.2%    (19.6%)
Americas            176,000     6,954    170,000    5,994    3.5%     16.0%
EMEA                124,000     4,484    119,000    4,626    4.2%     (3.1%)
Total               1,179,000   66,385   895,000    54,028   31.7%    22.9%

"Actives" are persons who purchased products directly from the company during
the previous three months.

"Sales Leaders" are persons who have completed and who maintain specified
sales requirements. Sales Leaders include our independent distributors who
have completed and who maintain specified sales requirements, and our sales
employees and contractual sales promoters in China, who have completed certain
qualification requirements.

SOURCE Nu Skin Enterprises, Inc.

Website: http://www.nuskin.com
Contact: Investors, Scott Pond (801) 345-2657, spond@nuskin.com, or Media,
Kara Schneck (801) 345-2116, kschneck@nuskin.com
 
Press spacebar to pause and continue. Press esc to stop.